Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Change in Taxes (2025)

Keros Therapeutics (KROS) has disclosed Change in Taxes for 1 consecutive years, with -$1.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Taxes changed N/A year-over-year to -$1.9 million, compared with a TTM value of $2.2 million through Dec 2025, changed N/A, and an annual FY2025 reading of $2.2 million, changed N/A over the prior year.
  • Change in Taxes was -$1.9 million for Q4 2025 at Keros Therapeutics, up from -$2.2 million in the prior quarter.
  • Across five years, Change in Taxes topped out at $10.0 million in Q1 2025 and bottomed at -$3.7 million in Q2 2025.